When it comes to the pharmaceutical industry, there is no disputing the fact that they handle vast amounts of sensitive data; ranging from proprietary research and development information to personal health records and clinical trial results. 

As cyber threats grow increasingly sophisticated, protecting this sensitive information from unauthorized access and potential breaches is critical. The stakes are understandably high, as this data is not only the backbone of life-saving drugs and therapies but also a prime target for cybercriminals. 

Thankfully now in the digital age there is a diverse range of cybersecurity measures pharmaceutical companies can adopt: from cloud and network security to compliance regulations and maintaining a strict chain of custody. However, even with these measures in place, the threat of a breach can last long after a drive has reached the end of its lifecycle, which is why high security data decommissioning is another crucial aspect of proper cybersecurity. 

Importance of Compliance Regulations

Pharmaceutical companies operate in a highly regulated environment where compliance is critical. Regulatory bodies like the U.S. Food and Drug Administration (FDA), the Health Insurance Portability and Accountability Act (HIPAA), and the EU’s General Data Protection Regulation (GDPR), among others, have stringent guidelines concerning data management. These guidelines also include what constitutes as proper destruction, an aspect of data security that we argue is the most important. 

These guidelines are in place to prevent unauthorized access to confidential information, safeguard patient privacy, and to maintain the integrity of research data. If a pharmaceutical company fails to comply with these regulations, it can result in severe penalties, including hefty fines, legal action, damage to their reputation, and of course, adverse effects on the lives of their patients. 

Critical Compliance Regulations

Regulations like the FDA’s 21 CFR Part 11, which governs electronic records and electronic signatures, require that companies implement robust controls to ensure data integrity and security. Part 11 requires that any actions taken on electronic records, including their destruction, be recorded in an audit trail. This documentation provides validated proof that the records were destroyed in compliance with regulatory standards and that the process was carried out by authorized personnel, ensuring that patient signatures remain secure. This kind of documentation is called a chain of custody, which we will discuss in-depth later on in this blog. 

Similarly, the EU’s General Data Protection Regulation (GDPR) mandates strict data protection measures. Pharmaceutical companies conducting medical trials in Europe are required to comply with GDPR regulations, including the mandate that patient data should never leave the clinical site and is only accessible by authorized personnel. 

For example, pharmaceutical companies must obtain explicit consent from their patients before collecting and processing their personal data. It also requires companies to implement strict security measures to protect data from unauthorized access or disclosure, including the secure disposal of personal data when it is no longer needed. Compliance with these regulations is not optional—it is a legal requirement that ensures the trust and safety of all stakeholders involved.  

One of the most prominent regulations is the Health Insurance Portability and Accountability Act (HIPAA). HIPAA establishes national standards for protecting patient health information, requiring pharmaceutical companies to implement robust safeguards when handling, storing, and transmitting patient data. This includes ensuring that data is encrypted, access to information is restricted, and that there are protocols in place to detect and respond to potential data breaches. Companies must also provide patients with rights over their data, such as the ability to access and request corrections to their health information. 

Francesco Ferri, an OT security deployment and operations lead at GSK, a global biopharma company, told Industrial Cyber that, “a key factor that sets the pharmaceutical sector apart is that integrity takes priority over availability. Safety is always the main focus.”

We couldn’t agree more. After all, high-security data destruction equipment is essential for meeting these regulatory requirements.

Criticality of High Security Data Destruction

Beyond compliance and the implementation of the most robust cybersecurity defenses, the need for high security data destruction measures is driven by the critical need for data security and patient privacy. The pharmaceutical industry is a lucrative target for cyberattacks due to the high value of the data it holds. From clinical trial results to proprietary formulas, the information stored by these companies is highly sought after by hackers and competitors. 

Traditional methods of data decommissioning, such as deleting or overwriting files, is not a sufficient form of destruction, especially now in an era where data recovery technologies have advanced significantly. Given the uptick in the storage capacity of hard drives, proper decommissioning is crucial in safeguarding sensitive information. High-security data destruction equipment ensures that data is irretrievably destroyed, leaving no possibility for reconstruction. 

Without proper destruction protocols, sensitive information can be retrieved, leading to breaches that could compromise patient safety, intellectual property, and an advantage for competitors. A breach of this data, in any capacity, could have catastrophic consequences, including the theft of intellectual property, which could cost billions in lost revenue, or the manipulation of research data, potentially leading to unsafe products reaching the market. 

Even though the pharmaceutical industry is worth over a trillion dollars, the average cost of a data breach is approximately $4.88 million, which can still gravely affect the average pharmaceutical company.

Chain of Custody’s Role in Data Security

It would be irresponsible of us to discuss proper compliance regulations and the criticality of high security data destruction in-depth without talking about the vital importance of creating and maintaining a chain of custody.

A chain of custody is strictly detailed documentation of the data’s handling, movement, access, and activity throughout its lifecycle. This type of documentation, which should only ever be handled by authorized personnel, is crucial not only for compliance and auditing purposes, but also in ensuring that the data has been securely destroyed once it reaches end-of-life. A chain of custody and secure data decommissioning procedure should always go hand-in-hand.

Conclusion

A robust cybersecurity system, compliance with regulatory mandates, a documented chain of custody, and a high security data decommissioning process combine to create a comprehensive framework for safeguarding sensitive information, ensuring data integrity, and mitigating risks throughout the entire data lifecycle. In doing so, pharmaceutical companies can reinforce the trust that stakeholders, including patients, partners, and regulators, place in their hands. 

Protecting this information through proper data destruction and cybersecurity practices are not just regulatory obligations but moral ones, as well. It shows a commitment to safeguarding the dignity and privacy of individuals who rely on pharmaceutical companies to act responsibly. Our very lives depend on it.